Sanovel is a pharmaceutical company established by the pharmacist, Erol Toksöz in 1983 with 100% Turkish capital. Sanovel has been operating in the pharmaceutical sector for over 30 years, and today it has more than 1200 employees and a modern manufacturing facility. Sanovel is carrying Turkish pharmaceutics into future.  

Since the day it started manufacturing, Sanovel has made a name for itself with its dynamic structure open to change. Sanovel has had a voice in Turkish pharmaceutical sector with its investments in human resources and R&D.

Sanovel İlaç’s new medicine manufacturing facility was founded in Silivri Çatatlköy on November 3, 2001, and it started manufacturing in April 2006. As the new manufacturing facility, which was equipped with the latest technology, started its operations, it had already completed its infrastructure and investments to serve in international markets.

Sanovel has been working in international markets since 2005, primarily in Balkan countries and Commonwealth of Independent States.  Georgia, Azerbaijan, Kazakhstan, Kyrgyzstan, Uzbekistan, Russia, Ukraine, Iraq, Albania and Turkmenistan are among the countries to which Sanovel exports. Sanovel’s first exports to European Union countries started with Spain in 2017. Sanovel was certified by FDA, considered to be the greatest health authority in the world, after the audits that took place between 3 and 11 September 2018. Following this success, Sanovel made an important step to export medicine to the USA, too.


Sanovel İlaç works on products that are used for cardiovascular, respiratory, central nervous and gastrointestinal systems as well as antidiabetic, antihistaminic, antiasthmatic, analgesic, antiviral, antifungal and antibiotic medicines.  

Sanovel posits quality as a fundamental principle, prioritizes medical ethics, values respect for human and environment and attaches importance to customer satisfaction. Aiming at perfection, Sanovel is an innovative company open to change and development. Sanovel is a company aware of its corporate and social responsibilities and operates in line with those responsibilities.

As the first Turkish company to get a license from the US Patent and Trademark Office for four pharmaceutical formulations it has developed, Sanovel has reached an admirable achievement.   The medicine formulations, which Sanovel developed completely with Turkish capital, are guaranteed the license protection right by the US until 2033.

Sanovel has been rapidly and consistently growing since its very establishment. It adds value to the sector through its R&D activities. It is now among the highest-ranking pharmaceutical companies on the list of pharmaceutical companies by revenue in Türkiye.